These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38309469)

  • 1. Dyslipidaemia in elderly and stroke patients.
    Kahali D
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S75-S79. PubMed ID: 38309469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review.
    Chang Y; Eom S; Kim M; Song TJ
    Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India.
    Puri R; Mehta V; Iyengar SS; Srivastava P; Yusuf J; Pradhan A; Pandian JD; Sharma VK; Renjen PN; Muruganathan A; Krishnan M; Srinivasan AV; Shetty S; Narasingan SN; Nair DR; Bansal M; Prabhakar D; Varma M; Paliwal VK; Kapoor A; Mukhopadhyay S; Mehrotra R; Patanwala RM; Aggarwal R; Mahajan K; Kumar S; Bardoloi N; Pareek KK; Manoria PC; Pancholia AK; Nanda R; Wong ND; Duell PB
    Curr Vasc Pharmacol; 2022; 20(2):134-155. PubMed ID: 34751121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing dyslipidaemia in patients with chronic kidney disease.
    Mehta A
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S90-S92. PubMed ID: 38278323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment.
    Masana L; Plana N; Andreychuk N; Ibarretxe D
    Pharmacol Res; 2023 Apr; 190():106738. PubMed ID: 36940892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyslipidemia in diabetes.
    Kalra S; Raizada N
    Indian Heart J; 2024 Mar; 76 Suppl 1(Suppl 1):S80-S82. PubMed ID: 37956957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypercholesterolemia and cardiovascular risk].
    Sinning D; Landmesser U
    Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-Modifying Therapies and Stroke Prevention.
    Hackam DG; Hegele RA
    Curr Neurol Neurosci Rep; 2022 Jul; 22(7):375-382. PubMed ID: 35554824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ
    Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
    Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
    Page MM; Watts GF
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):299-312. PubMed ID: 25861882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets in the treatment of dyslipidaemias: From statins to PCSK9 inhibitors. Unmet needs.
    López-Miranda J; Pedro-Botet J
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():46-52. PubMed ID: 33966813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering therapy: Guidelines to precision medicine.
    Su X; Cheng Y; Chang D
    Clin Chim Acta; 2021 Mar; 514():66-73. PubMed ID: 33359059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.